Pfizer

The shortage comes as there has been a steady increase in rates of syphilis since 2000. Inventory can start depleting as early as this month, Pfizer said.

Pfizer said that tweaking its vaccine to better target the omicron variant is safe and works — just days before regulators debate whether to offer Americans updated booster shots this fall.

Pfizer plans to submit new data to the Food and Drug Administration this week, bringing families with young children one step closer to a long-awaited vaccine.

Data show that a third dose can help boost kids' immunity. Some experts are skeptical that another shot is needed for younger kids.

NPR has obtained the government's $5.3 billion contract for the first 10 million courses of Paxlovid, an antiviral pill for COVID-19. Here's what's in it.

Though people who are vaccinated and boosted appear to be better protected against omicron, the highly contagious variant has still led to breakthrough cases and a surge in infections worldwide.

The new recommendation for adolescents age 12-17 came hours after a panel of CDC advisers voted in favor of it. The boosters should be given five months after initial immunization.

The move to shorten the Pfizer booster interval comes as the U.S. shatters daily case records. The recommended interval for those who received Moderna or Johnson & Johnson vaccines has not changed.

The authorization comes in the midst of an explosion of COVID-19 cases nationwide driven by the omicron variant — a surge that has brought a spike in pediatric hospitalizations.

Pfizer and BioNTech, which produced the first COVID-19 vaccine authorized in the U.S., say they will expand ongoing trials to include a third dose for children as young as 6 months old.